Global Embolization Particle Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Embolization Particle Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Embolization is a minimally invasive therapy to stop bleeding as well as to stop blood flow to a tumor in order to shrink it or in preparation for removal. In this procedure, some embolized particles or substances are injected into the veins of the patients to block or reduce the blood flow to cancer cells. Embolization is an option for some patients with tumors that cannot be removed by surgery. It can be used for tumors that are too large to be treated with ablation (usually larger than 5 cm thickness). It can also be used with ablation. Embolization does reduce some of the blood supply to the normal liver tissue, so it may not be a good option for some patients whose liver has been damaged by diseases such as hepatitis or cirrhosis. Embolization is used in many procedures as a part of interventional radiology.

Market Overview:

The latest research study on the global Embolization Particle market finds that the global Embolization Particle market reached a value of USD 1915.55 million in 2022. It’s expected that the market will achieve USD 3468.24 million by 2028, exhibiting a CAGR of 10.4% during the forecast period.

Drivers

The Americas dominates the global embolic particle market. Good factors, high market maturity, technical and financial advantages, production capacity, and the development of new technologies, the availability of advanced hospital infrastructure and the availability of skilled healthcare professionals have further increased market growth.

Europe is paying more and more attention to the rapid diagnosis and treatment of cancer, changing lifestyles, increasing the prevalence of cancer in the elderly population, and occupying a second place in the market on the basis of an aging population.

The Asia Pacific region is the fastest growing market as there are more developing countries in the region, such as India and China. These countries are encouraging the development of health care. In addition, increasing the number of cancers in patients in developing countries will directly increase the demand for various diagnostic and therapeutic approaches, which in turn will drive market growth.

The Middle East and Africa are expected to have the smallest market share due to the low availability of medical facilities and the low growth in the medical sector. However, countries such as Qatar and Kuwait are paying more attention to the medical sector and developing medical facilities, which will drive the market in the region.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

Boston Scientific Corporation is one of the major players operating in the Embolization Particle market, holding a share of 22.27% in 2018.

Boston Scientific Corporation has entered into a definitive agreement to acquire the interventional radiology portfolio of CeloNova Biosciences, a San Antonio-based developer of endovascular and interventional cardiology technologies. The structured agreement includes drug-eluting microspheres designed to be loaded with chemotherapy drugs for delivery to cancerous tumors, and spherical embolic products used to treat uterine fibroids and other conditions. The transaction consists of an upfront payment of $70 million and additional payments contingent on regulatory and sales milestones.

Terumo Corporation announced recently that it has entered into an agreement (hereafter the acquisition ) to purchase Sequent Medical, Inc. (California, United States; hereafter Sequent ), a privately-held firm developing a new medical device for aneurysm embolization. The purchase price of $280M will be paid at closing, with up to $100M more to be paid based on the achievement of specific development or commercial milestones. The acquisition is a key element in Terumo’s new growth strategy to establish and expand its global presence in the neurovascular market and other rapidly growing markets. Terumo has also identified the cardiology and endovascular markets as potential areas for growth.

Segmentation Overview:

Among different product types, PVA segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Oncology segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Embolization Particle market covered in Chapter 3:

Terumo
Medtronic
Sirtex Medical Limited
Merit Medical
Cook Medical
BTG Medical
Boston Scientific Corporation
Hengrui

In Chapter 4 and Chapter 14.2, on the basis of types, the Embolization Particle market from 2018 to 2029 is primarily split into:

PVA
Microspheres
Gelfoam
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Embolization Particle market from 2018 to 2029 covers:

Oncology
Prostate Disease
Peripheral Vascular Disease
Neurology
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)